Analyst Ratings For NASDAQ:SRPT – Sarepta Therapeutics (NASDAQ:SRPT)
Today, Goldman Sachs raised its price target on NASDAQ:SRPT – Sarepta Therapeutics (NASDAQ:SRPT) to per share.
Some recent analyst ratings include
- 5/11/2018-Barclays Upgrade from a “Equal Weight ➝ Overweight” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:SRPT – Sarepta Therapeutics (NASDAQ:SRPT)
NASDAQ:SRPT – Sarepta Therapeutics (NASDAQ:SRPT) has insider ownership of 7.90% and institutional ownership of 85.21%.
- On 11/30/2017 Hans Lennart Rudolf Wigzell, Director, sold 6,667 with an average share price of $55.89 per share and the total transaction amounting to $372,618.63.
- On 11/8/2017 Douglas S Ingram, CEO, bought 38,138 with an average share price of $52.44 per share and the total transaction amounting to $1,999,956.72.
- On 11/6/2017 Shamim Ruff, SVP, sold 10,000 with an average share price of $55.00 per share and the total transaction amounting to $550,000.00.
- On 10/3/2017 Shamim Ruff, SVP, sold 11,500 with an average share price of $50.00 per share and the total transaction amounting to $575,000.00.
- On 7/27/2017 Douglas S Ingram, CEO, bought 47,058 with an average share price of $42.50 per share and the total transaction amounting to $1,999,965.00.
- On 7/21/2017 Shamim Ruff, SVP, sold 12,138 with an average share price of $42.97 per share and the total transaction amounting to $521,569.86.
- On 7/20/2017 Alexander Cumbo, SVP, sold 5,918 with an average share price of $41.00 per share and the total transaction amounting to $242,638.00.
Recent Trading Activity for NASDAQ:SRPT – Sarepta Therapeutics (NASDAQ:SRPT)
Shares of NASDAQ:SRPT – Sarepta Therapeutics closed the previous trading session at 91.22 down -0.63 0.69% with 91.22000122070312 shares trading hands.